Loading organizations...

§ Public · Pennsylvania Furnace, PA, USA
Clinical-stage biopharmaceutical company developing novel oncology therapeutics for global markets, focused on targeted cancer therapies.
ArriVent Biopharma is a clinical-stage biopharmaceutical company based in Newtown Square, Pennsylvania, that identifies, in-licenses, and develops novel oncology therapeutics from global markets for broader commercialization. The enterprise primarily focuses on advancing targeted cancer treatments, such as its lead candidate furmonertinib for non-small cell lung cancer, by acquiring development rights to international preclinical and clinical assets. The organization raised over $300 million across early venture capital rounds, including a $155 million Series B financing, before securing approximately $175 million in a January 2024 initial public offering on the Nasdaq. ArriVent is backed by prominent institutional investors including General Catalyst, Sofinnova Investments, OrbiMed, and Hillhouse Capital, and maintains a strategic development partnership with Allist Pharma. ArriVent Biopharma was officially founded in 2021 by former Viela Bio chief executive officer Dr. Bing Yao and Dr. Stuart Lutzker.
ArriVent Biopharma has raised $465.0M across 3 funding rounds.
ArriVent Biopharma has raised $465.0M in total across 3 funding rounds.
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing differentiated medicines for unmet needs in oncology and other difficult-to-treat diseases.[1][2] Its lead candidate, firmonertinib, a tyrosine kinase inhibitor targeting epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), is in Phase 3 trials for exon 20 insertion mutations and Phase 1b for other EGFRm variants; the company also advances ARR-217 (antibody-drug conjugate for gastrointestinal cancers) and ARR-002 (for solid tumors).[1][2] Serving patients with advanced cancers, ArriVent addresses gaps in treatments for specific mutations often underserved by existing therapies, leveraging in-licensing from global partners like Allist Pharmaceuticals.[1][2] With 52 employees and an IPO in January 2024, it shows growth momentum through strategic collaborations and a pipeline poised for regulatory paths.[1]
Founded in 2021 and headquartered in Newtown Square, Pennsylvania, ArriVent emerged to bridge innovative therapies developed outside the U.S.—particularly in China, Europe, South Korea, and Japan—to global markets.[1][2] CEO Zhengbin Yao leads a team of oncology experts with proven regulatory experience, drawn from the recognition that many promising drugs risk limited reach beyond their origin geographies.[2] The idea crystallized around in-licensing high-potential candidates like firmonertinib from Shanghai Allist Pharmaceuticals, marking early traction via partnerships with Aarvik Therapeutics, Beijing InnoCare Pharma, Jiangsu Alphamab, and Lepu Biopharma.[1][2] This pivot to "R&D done differently" emphasized selective preclinical/clinical-stage assets with clear approval paths, humanizing the company's drive to democratize access to novel oncology treatments.[2]
ArriVent rides the wave of global biopharma globalization, capitalizing on Asia's oncology innovation boom—especially China's EGFR-targeted therapies amid rising NSCLC incidence worldwide.[2] Timing aligns with post-IPO momentum (2024) and unmet needs in mutation-specific cancers, where standard treatments falter, fueled by market forces like aging populations and precision medicine demand.[1] By in-licensing and optimizing for U.S./global approvals, it influences the ecosystem by reducing development risks for originators, fostering cross-border pipelines, and accelerating patient access in a $100B+ oncology market.[2]
ArriVent's trajectory hinges on firmonertinib Phase 3 readout, potentially yielding a first-in-class EGFR exon 20 therapy and blockbuster potential, alongside ADC expansions amid surging interest in targeted payloads.[1][2] Trends like AI-driven mutation profiling and China-West partnerships will shape its path, evolving its role from licensor to integrated global player if approvals materialize by 2026-2027. Watch for expanded collaborations to diversify beyond oncology, amplifying its mission to globalize differentiated medicines.[2] This positions ArriVent as a nimble bridge in biopharma's fragmented innovation landscape.
ArriVent Biopharma has raised $465.0M across 3 funding rounds. Most recently, it raised $155.0M Series B in March 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 27, 2023 | $155M Series B | Elena Viboch, James Healy | Aihc Capital, Catalio Capital, HBM Healthcare Investments, Hongshan Capital Group (Sequoia Capital China), Infinitum Asset Management, Lilly Asia Ventures, Octagon Capital, Carl Gordon, Shanghai Healthcare Capital, Sirona Capital, Terra Magnum Capital Partners, Unicorn Capital, ZOO Capital | Announced |
| Dec 1, 2022 | $160M Series B | — | Dimension Capital, General Catalyst, OrbiMed, Soffinova Partners, Sofinnova Investments, SR ONE, Third Rock Ventures, Westlake Village BioPartners | Announced |
| Jun 30, 2021 | $150M Series A | Hillhouse Capital Group | Lilly Asia Ventures, Lyra Capital, Octagon Capital, OrbiMed, ZOO Capital | Announced |
ArriVent Biopharma has raised $465.0M in total across 3 funding rounds.
ArriVent Biopharma's investors include Elena Viboch, James Healy, AIHC Capital, Catalio Capital Management, HBM Healthcare Investments, Hongshan Capital Group (Sequoia Capital China), Infinitum Asset Management, Lilly Asia Ventures, Octagon Capital, Carl Gordon, Shanghai Healthcare Capital, Sirona Capital.